Goldman Sachs analyst Rajan Sharma suspended the firm’s investment rating, price target and earnings estimates for Idorsia (IDRSF) Pharmaceuticals with “insufficient information on which to base an investment view.” The company has stated it needs additional funding as its liquidity does not cover its negative cash flow for the next twelve months of its business plan, the analyst noted.
Don't Miss our Black Friday Offers:
- Unlock your investing potential with TipRanks Premium - Now At 40% OFF!
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IDRSF: